Assessment of interleukin 32 as a novel biomarker for non-alcoholic fatty liver disease

Egyptian Liver Journal

Table 1 Demographic and clinical characteristics of all participants

	NAFLD cases	Controls	P value
Age (years)	49.40 ± 12.01	45.66 ± 10.33	0.140
Sex
Male	13 (32.50%)	21 (52.50%)	0.070
Female	27 (67.50%)	19 (47.50%)	0.070
Special habits
Non-smoker	30 (75.00%)	32 (80.00%)	0.592
Smoker	10 (25.00%)	8 (20.00%)	0.592
Hypertension
No	25 (62.5%)	40 (100%)	< 0.001
Yes	15 (37.5%)	0 (0.00%)	< 0.001
Weight (kg)	93.96 ± 12.64	72.02 ± 7.37	< 0.001
Height (cm)	165.16 ± 4.69	167.50 ± 6.67	0.074
Body mass index	34.31 ± 4.03	25.70 ± 2.53	< 0.001
Waist (cm)	98.10 ± 10.76	78.12 ± 4.65	< 0.001
Interleukin 32 serum levels (pg/mL)	76 (45.5-111.125)	13 (8-15)	< 0.001
Aspartate aminotransferase IU/L	52.05 ± 12.44	28.72 ± 5.58	< 0.001
Alanine aminotransferase IU/L	60.35 ± 16.92	33.17 ± 4.42	< 0.001
Total bilirubin mg/dL	0.67 ± 0.29	0.72 ± 0.26	0.451
Albumin g/dL	3.55 ± 0.42	4.26 ± 0.45	< 0.001
Total glycerides mg/dL	210.85 ± 23.74	131.80 ± 14.60	< 0.001
Total cholesterol mg/dL	230.32 ± 25.97	170.70 ± 17.53	< 0.001
High-density lipoprotein mg/dL	29.17 ± 3.56	37.15 ± 6.26	< 0.001
Low-density lipoprotein mg/dL	160.65 ± 25.93	106.25 ± 19.03	< 0.001

Variables were shown as frequency and percentages for categorical variables, mean and standard deviation for parametric numerical variables, and median (interquartile range) for non-parametric numerical variables